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1148-114 Atrial Fibrillation Does Not Degrade the Clinical Benefits 
From Enhanced External Counterpulsation Therapy in 
Patients With Chronic Angina: Results From the 
international EECP Patient Registry 
Anthonv 8. Ochoa William O’Neill, Steve Almany. William Beaumont Hospital, Royal 
Oak, Ml 
Background: EECP is a non-invasive analog of the intra-aortic balloon pump, and IS 
effective in treating chronic refractory angina pectods. Frequent triggering interference 
caused by the irregular rhythm of atrial fibrillation (AF) may diminish the clinical benefits 
of EECP. Methods: The International EECP Patient Registry enrolls consecutive patients 
undergoing EECP for chronic angina. We analyzed demographics and clinical outcome 
data from 1485 patients from > 90 international sites. 213 had AF, and 1272 did not have 
atrial fibrillation (NAF). EECP was given l-2 hrs daily to all patients and each group had 
similar total treatment hours (mean+/-SD, 33 f 10hrs) and completion rates (80% vs 
83%). Results: Patients with AF were older (70 f IO vs 66 f 10 yrs), and had a higher 
incidence of prior Ml (78% vs 69%) and history of congestive heart failure (54% YS 31%); 
all pcO.005. A similar decrease in the frequency of nitroglycerine use (mean&D, -7.4 * 
9.1 vs -6.9 * 10.3 tabs/wk), angina1 episodes per week (-8.3 * 12 vs -7.7 f 10.3), and 
decrease >/=I angina class (76% YS 74%) occurred in both groups (all p=NS). Diastolic 
augmentation was the same in both groups as assessed by peak-to-peak and area under 
the curve pressure ratios (Table 1). Adverse cardiac events and bleeding complications 
occurred infrequently in both groups (p=NS). Conclusions: Patients with AF receive the 
same clinical benefits from EECP as patients without AF, and EECP is well tolerated in 
AF patients. AF does not affect diastolic augmentation during EECP. 
Table 1. Effects of AF on Diastolic Augmentatmn Wlfh EECP 
i’st Hour of EECP Last Hour of EECP 
NAF AF NAF AF 
peak to peak 0.78 +I- 0.5 0.78 +I- 0.7 1 .OO +I- 0.6 0.97 +/- 0.8 
area 0.95 +/- 0.6 0.86 +//- 0.6 1.23 +I- 0.7 1.12 +/- 0.7 
p=NS for all 
1148-115 Enhanced External Counterpulsation for the Relief of 
Angina in Patients With Diabetes: A One-Year Clinical 
Outcome Study 
Georoiann C. Linnemeier, Elizabeth D. Kennard, Ozlem Soran, Sheryl F. Kelsey, 
University of Pittsburgh, Pittsburgh, PA 
Background: Diabetic patients (D) have less wccess with revascularization when com- 
pared with nondiabetic indiwduals (ND). Enhanced external counterpulsation (EECP) is a 
noninvasive analogue of the Intra-aortic balloon pump designed to increase myocardial 
perfusion pressure and decrease cardiac workload. EECP has been demonstrated to be 
safe and effective for treating angina in diabetic patients; however, the long-term effec- 
tiveness of EECP for the treatment of angina in this group of patients is unknown. 
Methods: The International EECP Patient Registry enrolls consecutive patients under- 
going EECP for chronic angina. We analyzed data from 1532 patients who were followed 
for one year after completion of treatment. Patients were divided into D (665) and ND 
(667). EECP was administered with similar total treatment hours (mean, 32 hours) and 
completion rates. 
Results: D differed significantly from ND in female gender (35% vs 21%, p<O.OOl), his- 
tory of congestive heart failure (40% vs 25%, p<O.OOl) and non-cardiac vascular disease 
(35 % vs 22 %, p<O.OOl). There were no differences between the groups in age (66 
years), race (91% white), prior revascularization (86%), prior myocardial infarction (69%), 
or multivessel disease (81%). Most patients were not considered candidates for further 
revascularizatlon. Upon completion of treatment. 69 % of D and 72 % of ND (p=NS) had 
their Canadian Cardiovascular Society angina class reduced by 1 class. This response 
was maintained at one year with 71.5% of D and 72.7% of ND (p=NS) reporting mainte- 
nance of angina reduction. During the follow-up period, the rates of myocardial infarction 
and unstable angina were comparable in both groups; however, D had higher rates of 
congestive heart failure (13% vs 6 %, p~O.001). death (7.5 % vs 3.9 %, p<O.Ol) and car- 
diac hospitalization (33 % vs 26 %, p<O.Ol). 
Conclusion: EECP is an effective treatment option for the relief of angina in patients with 
diabetes mellitus. Angma relief was sustained at one-year follow-up in a population 
where the majority of patients are not candidates for further revascularization. 
on 704 patients who underwent EECP for angina and were enrolled in the IEPR between 
January 1998 and July 2000. 
Results: The mean age of patients in this cohorl was 66rlO years, 74% were male, 43% 
were diabetic, 68% had prior MI. 80% had multivessel coronary disease, 30% had CHF, 
86% had prior PCI or CABG, 67% had quit smoking, and 5% were current smokers. The 
mean duration of coronary artery disease (CAD) was IO+8 years, and 81% were no 
longer suitable candidates for further revascularization by PCI or CABG. The mean num- 
ber of angina episodes per week was 10+13. Three percent of patlents had class I 
angina, 13% had class Il. 61% had class Ill, and 23% had class IV. 82% patients com- 
pleted at least 35 hours of EECP. 11% stopped due to a clinical event, and 7% stopped 
due to patient preference. 71% had a reduction by at least one angina class at the end of 
treatment, while 28% had no change in angina class. The following adverse cardiac 
events were reported at two-year follow-up: unstable angina 19%, Ml lo%, death IO%, 
CHF exacerbation 13%. PCI 11%. CABG 6%. cardiac hosoitalization 40%. and reoeat 
EECP 19%. The angina status at two years was no angina in 30%, class I in 20%. class 
II in 28%. class Ill in 16%. and class IV in 6%. 59% of oatlents who reoorted a reduction 
in angina after the origmal EECP course had maintained that angina reduction at two 
years. 
Conclusion: In a large cohorl of patients with chronic CAD, EECP is associated with a 
significant reduction in angina that is sustained after two years of follow-up in the majority 
of cases. 
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848FO-2 Clinical Outcomes of Over 800 Radial Artery Grafts 
Used in Coronary Bypass Surgery 
Edward P. Chen, Emir Veledar, Ellis L. Jones, Robert A. Guyton. William S. Weintraub, 
Emory University, Atlanta, GA 
Background: Coronary artery bypass grafting (CABG) is an established treatment for 
ischemic heart disease and is most commonly performed using an internal mammary 
artery (IMA) in combination with one or more saphenous vein grafts (SVG). The radial 
artery (RA) has recently reemerged as an potential additional arterial conduit for CABG. 
However, to date, little experience exists regarding patient outcomes with the use of this 
vessel in myocardial revasculatizatlon. In this study. the clinical results of patients receiv- 
ing a RA graft at the time of CABG were retrospectively examined. 
Methods: From January 1997 to December 2001, all patients who underwent CABG 
with a RA grafl combined with an IMA and/or SVG’s were reviewed. Results were also 
compared to those who had CABG using only an IMA and SVG’s during this time. The 
follow-up period was up to 5 years. 
Results: During the study interval, 892 patients underwent CABG with a RA graft while 
6378 patients underwent CABG using an IMA and SVG’s. There was no difference in the 
two groups with respect to operative mortality (1.7% vs 2.1%), peri-operative myocardial 
infarction (1.1% vs 1.3%). intra-aorfic balloon pump use (0.1% YS 0.4%), major arrhyth- 
mlas (6.2% YS 7.4%), neurological events (3.9% YS 4.3%), sternal wound infections 
(0.7% vs 0.9%), and pulmonary compkcations (2.3% vs 3.4%). When compared with 
patients who did not receive a RA graft, a significantly larger proportion of patients in the 
RA group had undergone prior CABG (15.4% vs 4.4%, p<O.OOOl). In addition, surwal 
was significantly better 1” patients who underwent CABG using a RA when compared to 
those who did not recewe a RA graft (94.2% vs 91 .I%, p<O.OOOl). 
Conclusions: Use of a RA conduit at the time of CABG does not adversely affect opera- 
tive morbidity and mortality when compared to CABG without a RA graft. Although a sig- 
mficantly higher percentage of patients in the RA group had undergone prewous CABG, 
suwival was higher when compared to patients who received only an IMA in combination 
with SVG’s. These data suggest that the RA graft appears to be an safe and wable addi- 
tional arterial conduit for myocardial revascularization. partwlarly in the setting of re- 
operative coronary surgery. 
ii:00 am 
1148-116 Two-Year Outcomes After Enhanced External 
Counterpulsation: Data From the International EECP 
Patient Registry 
Andrew D. Michaels. Georgiann Llnnemeier, Ozlem Soran, Elizabeth D. Kennard, 
University of California, San Francisco, San Francisco, CA, University of Pittsburgh. 
Pinsburgh, PA 
Background: The International Enhanced External Counterpulsation (EECP) Patient 
Registry (IEPR) enrolls consecutive patients undergoing EECP for chronic angina. The 
IEPR began in Januaty 1998. and patients have been enrolled from 72 centers. 
Methods: We analyzed demographic, hemodynamic. and two-year clinical outcome data 
848FO-3 Influence of Diabetes on Coronary Grafl Patency 
Mohammad Khan, Joseph F. Sabik, Ill, Eugene H. Blackstone, Penny L. Houghtaling, 
Bruce W. Lflle, Delos M. Cosgrove, Ill, The Cleveland Clinic Foundation, Cleveland, OH 
Background: Diabetes is associated with mcreased failure of percutaneous coronary 
interventions. To determine if diabetes is also associated with increased risk of coronary 
artery bypass graft failure, we compared graft patency in diabetics and nondiabetics. 
Methods: From 1972 to 1999, 50,278 patients underwent primary Isolated CABG, of 
whom 296 patients with diabetes, and 3,203 patients without, had 12,488 complete post- 
operative angiograms. Grafts with no stenosis greater than 50% were considered patent. 
A propensity score was developed to adjust analyses for differences between diabetics 
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and nondiabetics. Longitudinal mixed model analyses accounted for multiple catheteriza- 
tions and multiple grafts per patient. 
Results: Slightly fewer in situinternal thoraclc attely (ITA, n=2,394) and saphenous vein 
grafts (SVG, n=l0,018) were patent across time in diabetics than in nondiabetics 
(P=.OO6; Figure). Risk-adjusted patency declined progressively for both types of conduit 
(Pc.OOl), but the decline was more rapid for SVGs (Pc.001). 
Conclusion: Unlike percutaneous coronary interventions, coronary awry bypass graft 
patency is similar in diabetics and nondiabetics. Therefore, coronary artery bypass SUP 
gery should be as durable in diabetics as nondiabetics. 
(EF) was 22.7 %. The mean number of grafts was 2.5 per patient. Myoblast Cells were 
delivered successfully in all subjects without any injection-related complications. Purity of 
the cells ranged from 47% lo 98% CD56+ myoblasts. Nine months follow-up revealed no 
significant adverse events associated with either cell transplantation or the injection pro- 
cedure. One patient had non-sustained ventricular tachycardia. Echocardiography, PET 
and MRI scans showed evidence of viability in the area df grafted scar. The mean EF 
improved from 22.7% to 35.9%. 
Conclusion: These preliminary data suggest that autologous myoblast cell transplanta- 
tion. within an infarcted myocardium during CABG. was feasible and safe. Improvement 
in viability and wall thickness is encouraging. Future cllnical trials evaluating the effect of 
autologous myoblast cell transplantation on left ventricular function are warranled. Final 
results on 12 patients will be presented. 
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84BFO-6 Combined Angioplasty and Robotic Coronary Bypass 
Surgery in Multivessel Coronary Artery Disease 
Kenneth D. Stahl, Kenneth R. Fromkin, And@ Bochenek, Douglas W. Boyd, Thomas A. 
Vassiliades, Hratch L. Karamanoukian, Marek Cisowski, Cleveland Clinic Florida, 
Weston, FL 
Background: Long-term benefits of a left internal mammary artery graft (LIMA) to the left 
anterior descending coronary arlery (LAD) are well known. This can now be accom- 
plished with minimally invasive robotic surgery without stemotomy or cardiopulmonary 
bypass. A four institution trial of a hybrid revascularizatu- strategy involving minimally 
invasive surgery for LIMA graft to the LAD and percutaneous coronary intewantion (PCI) 
to non-LAD vessels is reporied for multivessel disease. 
Methods: 150 patients ware treated with robotic endoscoplc LIMA grafts to the LAD and 
PCI to non-LAD vessels. All surgery was carried out using the Aesop or Zeus intra-oper- 
ative robotic devices. No patient recewed a stern&my incision or was placed on car- 
diopulmonary bypass. PCI was performed on non-LAD vessels before or after surgery. 
Results: 317 vessels were treated in 150 patients (2.1 vessels/patient). There were no 
early or late mortalities. Based on “Intention to tread all patlents were deemed totally 
revascularlzed in this hybrid manner. Complications included two intra-operative myocar- 
dial infarctions during surgaly (1.5%) and 1 (0.73%) stroke during PCI. Follow-up was 
complete in 1361150 (90.1%) patients at a mean post-procedure time of 12.1 (0.5 - 35) 
months. Post-procedure angina class was 1 .I (1 - 2). 79 (52.3%) patients had follow-up 
angiogram at 13.1 (0.3 35) months, 100% of LIMA grafts were patent. 77/79 (97.5%) 
were Fitzgibbon ‘A’, 2i79 (2.5%) Fltzgibbon ‘8’. 12/79 (15.2%) PCI vessels showed 
angiographic restenosis and 3/79 (3.8%) were occluded. 10 (7.3%) patients underwent 
repeat PCI, none had repeat surgery. 
Conclusion: A hybrid revascularization strategy of atraumatic robotic LIMA grafting lo the 
LAD combined with PCI of non-LAD vessels can be carried out with minimal complica- 
tions. outstanding 1 year LAD patency rates, and excellent symptom relief in patients 
with multivessel coronary artery disease. This hybrid procedure combines the best of 
surgical and catheter based therapy in a minimally invasive manner. 
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848FO-4 Cardiac Outcome and Cost-Effectiveness One Year 
After Off-Pump and On-Pump Coronary Artery Bypass 
Surgery: Results From a Randomized Study 
Hendrik M. Nathoe. Diederik van Dljk. Erik W. Jansen, Willem J. Suyker, Jan C. 
Diephuis, Wim Jan van Boven, Aarl Brute! de la Riviera Cornelius Borst, Cor J. 
Kalkman, Diederick E. Grobbee, Erik Buskens, Peter P. de Jaegere, The OCTOPUS 
Study Group, University Medical Center Utrecht, Utrecht, The Netherlands. Isala Clinics, 
Zwolle. The Netherlands 
Background: Avoiding cardiopulmonary bypass during coronary artery bypass surgety 
may reduce perioperative morbidity and costs. It is, however, unknown whether cardiac 
outcome is similar to bypass surgery using cardiopulmonary bypass. The purpose of this 
study was to compare cardiac outcome and cost-effectiveness at one year between 
bypass surgery on the beating heart (off-pump surgery) and conventional bypass surgery 
with the use of cardiopulmonary bypass (on-pump surgery). 
Methods: In a multicenter randomized clinical trial, 142 patients were randomly assigned 
to off-pump surgery and 139 patients to on-pump surgely. Cardiac outcome, cost-effec- 
tiveness and grafl patency ware determined at one year after surgery. The uncertainty 
surrounding the cost-effectiveness analysis was addressed by standard bootstrap tech- 
niques. 
Results: At one year, survival free from stroke, myocardial infarction and coronary rs- 
intervention was 88.0% after off-pump and 90.6% after on-pump surgery (p=O.48). Sur- 
vival free from angina was 89.3% versus 89.0% (p=O.93), respectively. Grafl patency 
determined in a randomized subset of patients, was 91% in the off-pump and 93% in the 
on-pump group (p=O.65). Off-pump surgery reduced costs by $2329 (13.1%) per patient 
($15479 versus $17808; pcO.01). Quality adjusted lifetime after off-pump and on-pump 
surgery was 0.82 versus 0.83 year (p=O.70). The cost-effectiveness ratio for off-pump 
compared with on-pump surgery as estimated by bootstrapping, remained in 98% of esti- 
mates below the conservative ‘willingness to pay’ threshold of $20,000 per quality 
adjusted life year. 
Conclusions: At one year, off-pump surgery was more cost-effective than on-pump sw 
gery. while maintaining comparable cardiac outcome. In selected patients, off-pump sur- 
gary as an alternative for on-pump surgery is justified from an economic perspective. 
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1170-l 00 A Single Troponin I Concentration Measured 12 Hours 
After Onset of Chest Pain Accurately Reflects infarct 
84BFO-5 Safety and Feasibility of Autologous Myoblast 
Size as Measured by Gadolinium-DTPA Late 
Transplantation in Patients Undergoing Coronary 
Enhancement Magnetic Resonance Imaging 
Artery Bypass Grafting: Results From the United States Thomas N. Martin, Bjoern A. Groenning, Tracey Steedman, John E. Foster, Alex T. 
Experience Elliott, Henry J. Dargv?, Glasgow Cardiac Magnetic Resonance Unit, Glasgow, United 
Kinodom 
Nabil Dib Patnck McCarthy. Ann Campbell, Johnathan Dinsmore, Michael Yeager, W. R -1 
MacLellan. Grew Fonarow. Robert E. Michler. Diane Buchele. Marwan Ghazoul. 
Edward B..Diath&h, Arizona Heart Institute, Phoenix, AZ 
Background: Autologous myoblast cell transplantation to repair myocardial infarction 
has been shown to be safe and effective in preclinical studies. The objective of this study 
was to demonstrate the feasibility and safety of myoblast transplantation in humans. 
Methods: Patients scheduled to undergo elective coronary artery bypass grafting 
(CABG) ware enrolled in the US multicenter clinical trial over a one-year period. Subjects 
with previous myocardial infarction and a I& ventricular ejection fraction < 30% were eli- 
gible to participate. A skeletal muscle biopsy of approximately 2 to 5 grams was excised 
from each patient with subsequent isolation and expansion of myoblast cells over a 
period of 2-3 weeks. Between 3 and 30 direct injections of myoblasts were delivered into 
the area of infarction at the time of surgery using one of 4 escalating cell doses ranging 
from 10 million cells lo 300 million cells. Pre and post-injection ECG, echocardlogram, 
Halter monitoring, positron emission tomography (PET) and magnetic resonance imag- 
ing (MRI) were performed. 
Results: Eleven patients underwent autologous myoblast cell transplantation combined 
with CABG. The mean age of patients was 57 years. The mean baseline ejection fraction 
Background. The purpose of the study was to assess the relationship between the sin- 
gle measure of cardiac troponin I (Tnl) used in clinical practice (8 to 12 hours after onset 
of chest pain) and infarct size and left ventricular (LV) dimensions and systolic function 
as measured by magnetic resonance imaging (MR). 
Methods. 13 male and 6 female (mean (range) age=60 (37-83) years) incident hospital 
admisslons with acute coronary syndromes were consecutively recruited. 9119 (47%) 
were treated with primaly thrombolysis. Blood sampling for Tnl took place E-12 hours 
after onset of chest pain and samples for cratine kinase (CK) and CKMB were collected 
at admission, after 12 hours and at the MR scan. MR was performed at a median (range) 
of 69 (16-120) hours from onset of chest pain on a Siemens Sonata 1.5T system using a 
phased array chest coil. LV dimensions were evaluated by cinematographic (TrueFISP) 
breath-hold sequence. Late contrast enhanced (LE) MR was performed 15 minutes after 
peripheral injection of 0.2 mmollkg gadolinium-DTPA using a breath-hold segmented tur- 
boFLASH sequence with non-seledive inversion-recovery. Images were evaluated by 2 
independent and blinded observers. 
Results. Tnl (median (range) 24 (0.3-117) pg/ml) strongly correlated with LE volume 
(mean (SD) 13 (15) ml): r=O.El, p<O.OOOl and with LV ejection fraction (mean (SD) 59 
(9.7)%): r=-0.58. p=O.O009. Tnl was unrelated lo LV end-diaslollc (140 (36) ml) and end- 
